Commentary: pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome
- PMID: 22212060
- DOI: 10.1111/j.1365-2133.2011.10761.x
Commentary: pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome
Comment on
-
Pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: a critical appraisal.Br J Dermatol. 2012 Jan;166(1):7-11; discussion 11-4. doi: 10.1111/j.1365-2133.2011.10754.x. Br J Dermatol. 2012. PMID: 22212057 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources